(Click here for details)
Similar to a heart transplant, SynCardia’s Total Artificial Heart replaces both failing ventricles and the four native valves.
TUCSON, AZ--(Marketwire - March 31, 2011) - SynCardia Systems, Inc. announced today that the company’s Chairman and Chief Scientific Officer, Marvin J. Slepian, MD, has published an eight-page article in the spring issue of U.S. Cardiology, titled “The SynCardia Temporary Total Artificial Heart -- Evolving Clinical Role and Future Status.”
“The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformité Européene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today,” wrote Dr. Slepian, Professor of Medicine (Cardiology and Biomedical Engineering) at the University of Arizona. "...The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher ‘quality’ flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding.”
Also this month, an article Dr. Slepian co-authored, titled “Materials for multifunctional balloon catheters with capabilities in cardiac electrophysiological mapping and ablation therapy” was published in Nature Materials. The article discusses using materials that integrate directly with the thin elastic membranes of otherwise conventional balloon catheters to provide diverse, multimodal functionality suitable for clinical use.
Dr. Slepian also co-authored an article published in the Journal of the American Dental Association this month, titled “The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation.” The article discusses using subantimicrobial-dose-doxycycline (SDD) as an adjunct to periodontal maintenance therapy to help reduce systemic measures of inflammation associated with both periodontitis and coronary artery disease (CAD).
On March 8, for the second year in a row, Dr. Slepian presented on SynCardia’s Total Artificial Heart at the 2nd Annual Medical Devices Summit in Boston, MA.
About SynCardia Systems, Inc.
SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artificial Heart. There have been more than 900 implants of the Total Artificial Heart, accounting for more than 210 patient years of life on the device.
Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.
For additional information, please visit: http://www.syncardia.com or follow SynCardia on Twitter -- @SynCardia_News
Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660
